Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Part of paid clinical trials in Duarte, California.
- Sponsor
- NeoImmuneTech
- Study ID
- NCT05075603
- Phase
- PHASE1
- Status
- Completed
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Diffuse Large B-cell Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Efineptakin alfa — DRUGNT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
- Tisagenlecleucel — DRUGAdministered as standard of care as described in the package insert on Day 0.
- Axicabtagene ciloleucel — DRUGAdministered as standard of care as described in the package insert on Day 0.
- Lisocabtagene Maraleucel — DRUGAdministered as standard of care as described in the package insert on Day 0.
Study Details
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.
Key Dates
- Start date
- Aug 6, 2021
- Status verified
- Oct 2025
- Primary completion
- Dec 18, 2024
- Completion
- Mar 12, 2025
Study Design
- Enrollment
- 17 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: NT-I7 after CAR-T (Kymriah, Yescarta, or Breyanzi) infusionCAR-T infusion administered per standard of care at Day 0 followed by NT-I7 on Day 21.
Primary Outcome Measure
For Dose Escalation Phase: Incidence of adverse events (AE) [ Time Frame: 21 Days ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | - |
| Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center | Detroit | Michigan | 48201 | - |
| Washington University in St. Louis | St Louis | Missouri | 63110 | - |
| Duke Cancer Institute | Durham | North Carolina | 27710 | - |
Find similar trials in Duarte, CA
Related Studies
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaPHASE2 · Recruiting · ImmunoVaccine Technologies, Inc. (IMV Inc.) · Fountain Valley, California
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaPHASE1 · Recruiting · AIDS Malignancy Consortium · Duarte, California
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California